Biotech Startups

Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions. The company's lead program, nizubaglustat, is currently in Phase 3 trials.

6 investors

Baebies develops multifunctional syndromic diagnostic testing using proprietary digital microfluidics, integrating molecular, immunoassay, chemistry, and coagulation testing into a single compact platform (FINDER) that runs on small-volume samples. Its products serve hospitals, clinics, pharmacies, and decentralized care settings for patients of all ages, having started with newborn and pediatric diagnostics.

6 investors

Beren is a public benefit corporation developing novel medicines in partnership with patients, caregivers, clinicians, and health systems. It focuses on advancing biology and chemistry to address the root causes of diseases.

6 investors

BioProtect develops a balloon spacer device for brachytherapy procedures, used to create spacing during cancer radiation treatment.

6 investors

Bio Protocol is a decentralized science (DeSci) platform where people can fund, develop and govern tokenized early-stage scientific research from universities, companies and researchers. It offers token-based fundraising, staking rewards, and a scientific AI agent framework, supporting an ecosystem of biotech DAOs focused on areas such as longevity, women's health, and rare diseases.

6 investors

BioAesthetics develops NACgraft, a cell-free, collagen-rich nipple-areolar complex graft that a surgeon applies so the patient's own cells integrate it into living nipple and areola tissue. It targets breast cancer survivors who have undergone mastectomies and lost their nipples, operating in the biomaterials and medical device field.

6 investors

BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security. It targets field-proven products serving homeland security, critical infrastructure, border, transportation, and public safety needs within a Detection, Analysis, and Response operational chain.

6 investors

BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions. It operates globally in the pharmaceutical and biotech industry.

6 investors

Birch Biosciences develops enzyme-based plastic recycling technologies using green chemistry and machine learning to transform plastic waste into reusable material. The company targets the plastic resin market with solutions for industrial and commercial recycling applications.

6 investors

BluumBio identifies and deploys naturally occurring enzymes from fungi, trees, and bacteria to remove industrial pollutants from soil, air, and water. The company serves environmental remediation projects requiring rapid decontamination of petroleum, pesticides, plastics, and other synthetic chemicals.

6 investors

BMC Ingredients produces Rhiza, a mycelium-based ingredient that serves as a whole-food, complete protein and clean-label additive for food manufacturers. It is used in animal-free products, as a meat enhancer to improve nutrition and mouthfeel, and as a protein and fiber boost in supplements and baked goods.

6 investors

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer. The company focuses on cancer immunotherapeutics and myeloid biology to address unmet patient needs.

6 investors

California Cultured uses plant cell culture technology to produce cocoa and chocolate without traditional farming, aiming to address sustainability and ethical concerns in cocoa supply. The company operates in the food technology and cellular agriculture space.

6 investors

Cadenza Bio develops small-molecule drugs for oral administration to treat demyelinating and inflammatory diseases. The company focuses on halting disease progression and promoting tissue repair in patients with debilitating conditions.

6 investors

Calysta produces protein ingredients through a patented fermentation platform that does not use arable land, plants, or animal products, offering products such as FeedKind and Positive Protein for animal feed and food. The company operates in cellular agriculture and food technology, with a FeedKind production plant in China run through its Calysseo partnership.

6 investors

Capable is a vertically integrated, AI-enabled deeptech platform developing peptide and nucleotide therapeutics using automated polymer synthesis, drawing on rare human genetic variants. Its first programs focus on sleep, targeting rare sleep diseases such as narcolepsy and hypersomnia with therapeutics aimed at improving cognitive performance under sleep deprivation.

6 investors

Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases. Acquired by Merck in 2023.

6 investors

Celerion is a contract research organization specializing in early phase clinical drug development, providing bioanalytical services and laboratory testing that generate clinical data for pharmaceutical clients. It focuses on early stage drug development to help clients make go/no-go decisions and bring drugs to market.

6 investors

CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers. The company focuses on cell fate control mechanisms to identify novel targets for cancer treatments and works with scientific and clinical centers of excellence.

6 investors

Cellibre engineers biological manufacturing by programming cells to produce industrial products through fermentation rather than traditional chemical synthesis. The company serves manufacturers seeking sustainable, cost-effective production of chemicals, materials, and other goods using cellular factories.

6 investors

Cellineobio develops cell engineering and bioprocess technology platforms. The company serves biotech and pharmaceutical research and manufacturing customers.

6 investors

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer. The company's approach combines engineered viral immunotherapy with potential combination therapies to improve patient quality of life.

6 investors

Checkerspot uses microalgae precision fermentation to produce specialized lipids and fats, including a bio-equivalent source of the sn-2 palmitate fat found in mother's milk, rare bioactive fatty acids, and tropical fat alternatives. Its ingredients serve the food, infant nutrition, and health and wellness markets, with partnerships aimed at scaling and commercializing these fats and oils.

6 investors

Pharmaceutical company developing medicines and vaccines for patient health and treatment. Operating for over 130 years with focus on clinical research and drug development.

6 investors